Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 303-308

  Dewar, Simon ^a   Reed, Lee C ^a   Koerner, Roland J ^a  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

Antimicrobial therapy; ESBLs; Gram negative; UTIs

Indexed keywords

BETA LACTAMASE INHIBITOR; EXTENDED SPECTRUM BETA LACTAMASE; MECILLINAM; PIVMECILLINAM;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; COMMUNICABLE DISEASE; CYSTITIS; DRUG EFFICACY; DRUG FORMULARY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROCOCCUS FAECALIS; ENZYME ACTIVITY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; HOST; HUMAN; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOKINETICS; PHARMACOLOGY; PSEUDOMONAS; REVIEW; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINA FLORA;

ANTIMICROBIAL THERAPY; ESBLS; GRAM-NEGATIVE; UTIS;

ADMINISTRATION, ORAL; AMDINOCILLIN PIVOXIL; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84892454825     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt368     Document Type: Review

References (66)

1. Nicolle LE. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol 2005; 16: 349-60.
2. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012;39: 283-94.
3. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-43.
4. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
5. Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 Suppl 1: 35-9.
6. Graninger W. Pivmecillinam-therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 2003; 22 Suppl 2: 73-8.
7. HPA, British Infection Association. Management of Infection Guidance for Primary Care for Consultation and Local Adaptation. London: HPA, 2010. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1279888711402(11 June 2013, date last accessed).
8. Scottish Intercollegiate Guidelines Network. Management of Suspected Bacterial Urinary Tract Infection in Adults. NHS Quality Improvement Scotland. 2012. http://www.sign.ac.uk/guidelines/fulltext/88/index.html (11 June 2013, date last accessed).
9. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother 2010; 65 Suppl 3: iii25-iii33.
10. Thomas K, Weinbren MJ, Warner M et al. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006; 57: 367-8.
11. Livermore DM, Hope R, Mushtaq S et al. Orthodox and unorthodox clavulanate combinations against extended-spectrum β-lactamase producers. Clin Microbiol Infect 2008; 14 Suppl 1: 189-93.
12. Lund F, Tybring L. 6β-amidinopenicillanic acids-a new group of antibiotics. Nature New Biol 1972; 236: 135-7.
13. Roholt K, Nielsen B, Kristensen E. Pharmacokinetic studies with mecillinam and pivmecillinam. Chemotherapy 1975; 21: 146-66.
14. Roholt K. Pharmacokinetic studies with mecillinam and pivmecillinam. J Antimicrob Chemother 1977; 3 Suppl B: 71-81.
15. Anderson JD, Adams MA. Urinary excretion of mecillinamby volunteers receiving film-coated tablets of pivmecillinamhydrochloride. Chemotherapy 1979; 25: 1-4.
16. Hares MM, Hegarty A, Tomkyns J et al. A study of the biliary excretion of mecillinam in patients with biliary disease. J Antimicrob Chemother 1982; 9: 217-22.
17. Grunberg E, Cleeland R, Beskid G et al. In vivo synergy between 6 β-amidinopenicillanic acid derivatives and other antibiotics. Antimicrob Agents Chemother 1976; 9: 589-94.
18. Wise R, Reeves DS, Symonds JM et al. A clinical investigation of pivmecillinam. A novel β-lactam antibiotic in the treatment of urinary tract infections. Chemotherapy 1976; 22: 335-9.
19. Spratt BG. Comparison of the binding properties of two 6 β-amidinopenicillanic acid derivatives that differ in their physiological effects on Escherichia coli. Antimicrob Agents Chemother 1977; 11: 161-6.
20. Spratt BG. The mechanism of action of mecillinam. J Antimicrob Chemother 1977; 3 Suppl B: 13-9.
21. Farrar WE. Amdinocillin. Ann Intern Med 1984; 101: 389-90.
22. Hanberger H, Nilsson LE, Svensson E et al. Synergic post-antibiotic effect of mecillinam, in combination with other β-lactam antibiotics in relation to morphology and initial killing. J Antimicrob Chemother 1991; 28: 523-32.
23. Tybring L, Melchior NH. Mecillinam (FL 1060), a 6β-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro. Antimicrob Agents Chemother 1975; 8: 271-6.
24. Baltimore RS, Klein JO, Wilcox C et al. Synergy of mecillinam (FL1060) with penicillins and cephalosporins against Proteus and Klebsiella, with observations on combinations with other antibiotics and against other bacterial species. Antimicrob Agents Chemother 1976; 9: 701-5.
25. Neu JC. Synergy of mecillinam, a β-amidinopenicillanic acid derivative, combined with β-lactam antibiotics. Antimicrob Agents Chemother 1976;10: 535-42.
26. Andersen BT, Joergensen M, Lorenzen J. Pivmecillinam in the treatment of therapy resistant urinary tract infections. A comparison with pivmecillinam, pivampicillin and their combination. Infection 1980; 8:27-31.
27. Tybring L. Mecillinam (FL 1060), a 6β-amidinopenicillanic acid derivative: in vitro evaluation. Antimicrob Agents Chemother 1975; 8:266-70.
28. Pitkäjärvi T, Pyykönen ML, Kannisto K et al. Pivmecillinam treatment in acute cystitis. Three versus seven days study. Arzneimittelforschung 1990;40: 1156-8.
29. Hovelius B, Mårdh PA, Nygaard-Pedersen L et al. Nalidixic acid and pivmecillinam for treatment of acute lower urinary tract infections. Scand J Prim Health Care 1985; 3: 227-32.
30. Granlund M, Landgren E, Henning C. Pivmecillinam in the treatment of Staphylococcus saprophyticus urinary tract infections. Scand J Infect Dis 1983; 15: 65-9.
31. Bruun JN, Digranes A, Bøe J et al. Treatment of Salmonella carriers with pivmecillinam alone or in combination with pivampicillin: experience with three patients. Scand J Infect Dis 1983; 15: 21-4.
32. Jonsson M. Pivmecillinam in the treatment of Salmonella carriers. J Antimicrob Chemother 1977; 3 Suppl B: 103-7.
33. Marre R, Schulz E. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal β-lactamases. Arzneimittelforschung 1998; 38: 863-5.
34. Sirot D, Chanal C, Henquell C et al. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to β-lactamase inhibitors. J Antimicrob Chemother 1994; 33: 1117-26.
35. Canica MM, Barthelemy M, Gilly L et al. Properties of IRT-14 (TEM-45), a newly characterised mutant of TEM-type β-lactamases. Antimicrob Agents Chemother 1997; 41: 373-8.
36. SougakoffW, Jarlier V. Comparative potency of mecillinam and other β-lactam antibiotics against Escherichia coli strains producing different β-lactamases. J Antimicrob Chemother 2000; 46 Suppl 1: 9-14.
37. Titelman E, Iversen A, Kahlmeter G et al. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 2011; 119: 853-63.
38. Fournier D, Chirouze C, Leroy J et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect 2013; 43:62-6.
39. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-β-lactamaseproducingEscherichia coli. AntimicrobAgentsChemother2010;54:4006-8.
40. Antipov AV. Chemotherapeutic effectiveness of mecillinam and dioxidine in an experiment using polyresistant Escherichia coli. Antibiot Med Biotekhnol 1987; 32: 683-5.
41. Livermore DM, Mushtaq S, Nguyen T et al. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. Int J Antimicrob Agents 2011; 37: 405-9.
42. Nicolle LE, Mulvey MR. Successful treatment of CTX-M ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis 2007; 39: 748-9.
43. Titelman E, Iversen A, Kalin M et al. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2012; 18: 189-92.
44. Zalmanovici TA, Green H, Paul M et al. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2010; issue 10: CD007182.
45. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003; 51: 69-76.
46. Schito GC, Naber KG, Botto H et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34:407-13.
47. Scheld WM, Fink FN, Fletcher DD et al. Mecillinam-ampicillin synergism in experimental Enterobacteriaceae meningitis. Antimicrob Agents Chemother 1979; 16: 271-6.
48. van der Voet GB, Mattie H, van Furth R. The antibacterial activity of combinations of mecillinam and ampicillin in vitro and in normal and granulopenic mice. Scand J Infect Dis 1983; 151: 91-6.
49. Eriksson S, Zbornik J, Dahnsjö H et al. The combination of pivampicillin and pivmecillinam versus pivampicillin alone in the treatment of acute pyelonephritis. Scand J Infect Dis 1986; 18: 431-8.
50. Igesund A, Vorland L. A fixed combination of pivmecillinam and pivampicillin in complicated urinary tract infections. A double-blind comparison with pivmecillinam. Scand J Infect Dis 1982; 14: 159-60.
51. Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002; 54: 589-98.
52. Ward TT, Amon MB, Krause LK. Combination amdinocillin and cefoxitin therapy of multiply-resistant Serratia marcescens urinary tract infections. Am J Med 1983; 75: 85-9.
53. Neu HC. Mecillinam, a novel penicillanic acid derivative with unusual activity against Gram-negative bacteria. Antimicrob Agents Chemother 1976; 9: 793-9.
54. Neu HC. Synergistic activity of mecillinam in combination with the β-lactamase inhibitors clavulanic acid and sulbactam. Antimicrob Agents Chemother 1982; 22: 518-9.
55. Anderson JD, Adams MA, Barrington JC et al. Comparison of the epidemiology of bacterial resistance to mecillinam and ampicillin. Antimicrob Agents Chemother 1976; 10: 872-7.
56. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of humanmicroflora. Lancet Infect Dis 2001; 1: 101-14.
57. Edlund C, Nord CE. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 Suppl A: 41-8.
58. Baines SD, O'Connor R, Huscroft G et al. Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 2009; 63: 838-9.
59. Sullivan A, Fianu-Jonasson A, Landgren BM et al. Ecological effects of perorally administered pivmecillinam on the normal vaginal microflora. Antimicrob Agents Chemother 2005; 49: 170-5.
60. Hooton TM. Pathogenesis of urinary tract infections: an update. J Antimicrob Chemother 2000; 46 Suppl A: 1-7.
61. Norinder BS, Norrby R, Palmgren AC et al. Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection. Antimicrob Agents Chemother 2006; 50: 1528-30.
62. Menday AP. Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection. Int J Antimicrob Agents 2002; 20: 297-300.
63. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: 103-20.
64. GrabeM, Bjerklund-Johansen TE, Botto H et al. Guidelines on Urological Infections. European Association of Urology. 2011; 112. http://www. uroweb.org/gls/pdf/15_Urological_Infections.pdf (11 June 2013, date last accessed).
65. André M, Vernby A, Odenholt I et al. Diagnosis-prescribing surveys in 2000, 2002 and 2005 in Swedish general practice: consultations, diagnosis, diagnostics and treatment choices. Scand J Infect Dis 2008; 40:648-54.
66. Linhares I, Raposo T, Rodrigues A et al. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis 2013; 13: 19.